Digital health funding rebounded in Q1 2026, reaching $4 billion across 110 deals, according to Rock Health data cited by reporting. The surge was driven primarily by “megadeals,” continuing a pattern where investors place larger bets on fewer companies as macro uncertainty persists. The funding mix points to a market preference for platforms with scalable commercialization pathways and clear differentiation, rather than earlier-stage aggregation of features. For biotech-adjacent digital therapeutics, payer-facing workflows, and clinical workflow tools, the capital flow signals that monetization narratives are increasingly decisive. Industry participants will likely watch whether Q1 momentum holds through late-stage deal activity and whether emerging categories can convert funding into durable revenue traction.